Combined treatment of All-trans retinoic acid with Tamoxifen suppresses ovarian cancer
Cancer Chemotherapy and Pharmacology · 2024
DOI: 10.1007/s00280-024-04671-7 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Chemotherapy and Pharmacology, 2024. Verfasst von Rui Xu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecology, East China Normal University Wuhu Affiliated Hospital, The Second People's Hospital of Wuhu City, No.259, Middle Jiuhua Roa…. Hauptthemen laut MEDLINE: Tamoxifen, Tretinoin, Ovarian Neoplasms, Apoptosis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Scientific Research Program of Anhui Provincial Health Care.
Abstract (Originalsprache)
Background
Ovarian cancer is a malignant tumor of the female reproductive system, and its mortality rate is as high as 70%. Estrogen receptor α (ERα)-positive ovarian cancer accounted for most of all ovarian cancer patients. ERα can promote the growth and proliferation of tumors.
Methods
The combined effect of All-trans retinoic acid (ATRA) and tamoxifen was obtained by the combination screening of tamoxifen and compound library by MTS. In addition, colony formation assay, flow cytometry analysis, immunofluorescence staining, quantitative real-time polymerase chain reaction (PCR), western blot, and tumor xenotransplantation models were used to further evaluate the efficacy of tamoxifen and ATRA in vitro and in vivo for ER-α-positive ovarian cancer.
Results
In our study, we found that All-trans retinoic acid (ATRA) can cooperate with tamoxifen to cause cell cycle arrest and apoptosis and inhibit ERα-positive ovarian cancer in vivo and in vitro. Further exploration of the mechanism found that ATRA can Inhibit genes related to the ERα signaling pathway, enhance the sensitivity of ERα-positive ovarian cancer cells to tamoxifen, and ascertain the effectiveness of tamoxifen and ATRA as treatments for ovarian cancer with an ERα-positive status.
Conclusion
Combination of ATRA and tamoxifen is a new way for the treatment of ERα-positive ovarian cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gynecology, East China Normal University Wuhu Affiliated Hospital, The Second People's Hospital of Wuhu City, No.259, Middle Jiuhua Road, Jinghu District, Wuhu, 241000, China.
- Department of Electrocardiogram, East China Normal University Wuhu Affiliated Hospital, The Second People's Hospital of Wuhu City, No.259, Middle Jiuhua Road, Jinghu District, Wuhu, 241000, China.
- Department of Gynecology, East China Normal University Wuhu Affiliated Hospital, The Second People's Hospital of Wuhu City, No.259, Middle Jiuhua Road, Jinghu District, Wuhu, 241000, China. fyjiang6872@163.com.
ORCID-Profile: Feiyun Jiang
Förderung
- Scientific Research Program of Anhui Provincial Health Care
Zitieren
APA
Xu, R., Yang, X., Tang, B., Mao, Y., & Jiang, F. (2024). Combined treatment of All-trans retinoic acid with Tamoxifen suppresses ovarian cancer. Cancer Chemotherapy and Pharmacology. https://doi.org/10.1007/s00280-024-04671-7
Vancouver
Xu R, Yang X, Tang B, Mao Y, Jiang F. Combined treatment of All-trans retinoic acid with Tamoxifen suppresses ovarian cancer. Cancer Chemotherapy and Pharmacology. 2024. doi:10.1007/s00280-024-04671-7
BibTeX
@article{Xu2024,
author = {Xu, Rui and Yang, Xiaowen and Tang, Bin and Mao, Yifan and Jiang, Feiyun},
title = {Combined treatment of All-trans retinoic acid with Tamoxifen suppresses ovarian cancer},
journal = {Cancer Chemotherapy and Pharmacology},
year = {2024},
doi = {10.1007/s00280-024-04671-7}
}
EUVIMED